Melanoma 抗体
Quick Overview for Melanoma 抗体 (ABIN6252231)
抗原
适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
纯化方法
- Protein G affinity chromatography
-
免疫原
- Melanocyte antigen was used as the immunogen for the Melanoma antibody PNL2.
-
亚型
- IgG1
-
-
-
-
应用备注
-
Immunofluorescence: 0.5-1 μg/mL
Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1)
Prediluted format: incubate for 30 min at RT (2)
Optimal dilution of the Melanoma antibody PNL2 should be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min. -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 0.2 mg/mL
-
缓冲液
- PBS with 0.1 mg/mL BSA and 0.05 % sodium azide
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- Aliquot and Store at -20C. Avoid freez-thaw cycles.
-
-
- Melanoma
-
背景
- Anti-PNL2 is a novel monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope id not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87 % ), as opposed to 76 % for anti-HMB45 and 82 % for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angio-myolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF.
抗原
-